ICRM
ICPT

Insight Capital Research & Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Insight Capital Research & Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-20,928
Closed -$6.9M – 154
2014
Q1 		$6.9M Buy
+20,928
New +$7.06M 1.59% 17

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Insight Capital Research & Management's ICPT Position: Q2 2014 in Review

Insight Capital Research & Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2014, closing a stake of 20,928 shares — an estimated $6.9M sold.

Insight Capital Research & Management first reported a position in ICPT in Q1 2014 and held it in 1 quarter. The position peaked at $6.9M in Q1 2014. 167 funds tracked by Wall St. Rank hold ICPT as of Q2 2014.

  • Insight Capital Research & Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Insight Capital Research & Management sold 20,928 Intercept Pharmaceuticals, Inc. shares in Q2 2014, an estimated $6.9M.
  • Insight Capital Research & Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • Insight Capital Research & Management's Intercept Pharmaceuticals, Inc. position peaked at $6.9M in Q1 2014.
  • 167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2014.

Based on Insight Capital Research & Management's 13F filing for Q2 2014, filed 13 Aug 2014.